ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Ocular Gene Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-39G17214
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Ocular Gene Therapy Market Research Report 2024
BUY CHAPTERS

Global Ocular Gene Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-39G17214
Report
November 2025
Pages:126
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
AbbVie
REGENXBIO
GenSight Biologics
Astellas
MeriaGTx
Neurophth Therapeutics
Innostellar Biotherapeutics
Exegenesis Bio
Zhongyin Technology

Ocular Gene Therapy Market

The global Ocular Gene Therapy market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
From a downstream perspective, Hospitals accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Ocular Gene Therapy leading manufacturers including AbbVie, MeriaGTx, Regenxbio, GenSight Biologics, Astellas, Neurophth Therapeutics, Innostellar Biotherapeutics, Exegenesis Bio, Zhongyin Technology, etc., dominate supply; the top five capture approximately % of global revenue, with AbbVie leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Ocular Gene Therapy market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Ocular Gene Therapy Market Report

Report Metric Details
Report Name Ocular Gene Therapy Market
Segment by Type
  • Gene Replacement Technology
  • Gene Editing Technology
  • Others
Segment by Application
  • Hospitals
  • Diagnostics Centers
  • Research Institutes
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company AbbVie, MeriaGTx, Regenxbio, GenSight Biologics, Astellas, Neurophth Therapeutics, Innostellar Biotherapeutics, Exegenesis Bio, Zhongyin Technology
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Ocular Gene Therapy study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Ocular Gene Therapy Market report?

Ans: The main players in the Ocular Gene Therapy Market are AbbVie, MeriaGTx, Regenxbio, GenSight Biologics, Astellas, Neurophth Therapeutics, Innostellar Biotherapeutics, Exegenesis Bio, Zhongyin Technology

What are the Application segmentation covered in the Ocular Gene Therapy Market report?

Ans: The Applications covered in the Ocular Gene Therapy Market report are Hospitals, Diagnostics Centers, Research Institutes

What are the Type segmentation covered in the Ocular Gene Therapy Market report?

Ans: The Types covered in the Ocular Gene Therapy Market report are Gene Replacement Technology, Gene Editing Technology, Others

1 Study Coverage
1.1 Introduction to Ocular Gene Therapy: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Ocular Gene Therapy Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Gene Replacement Technology
1.2.3 Gene Editing Technology
1.2.4 Others
1.3 Market Segmentation by Application
1.3.1 Global Ocular Gene Therapy Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Diagnostics Centers
1.3.4 Research Institutes
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Ocular Gene Therapy Revenue Estimates and Forecasts 2020-2031
2.2 Global Ocular Gene Therapy Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Ocular Gene Therapy Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Ocular Gene Therapy Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Gene Replacement Technology Market Size by Players
3.3.2 Gene Editing Technology Market Size by Players
3.3.3 Others Market Size by Players
3.4 Global Ocular Gene Therapy Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Ocular Gene Therapy Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Ocular Gene Therapy Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Ocular Gene Therapy Market Size by Type (2020-2031)
6.4 North America Ocular Gene Therapy Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Ocular Gene Therapy Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Ocular Gene Therapy Market Size by Type (2020-2031)
7.4 Europe Ocular Gene Therapy Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Ocular Gene Therapy Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Ocular Gene Therapy Market Size by Type (2020-2031)
8.4 Asia-Pacific Ocular Gene Therapy Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Ocular Gene Therapy Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Ocular Gene Therapy Market Size by Type (2020-2031)
9.4 Central and South America Ocular Gene Therapy Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Ocular Gene Therapy Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Ocular Gene Therapy Market Size by Type (2020-2031)
10.4 Middle East and Africa Ocular Gene Therapy Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Ocular Gene Therapy Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 AbbVie
11.1.1 AbbVie Corporation Information
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Ocular Gene Therapy Product Features and Attributes
11.1.4 AbbVie Ocular Gene Therapy Revenue and Gross Margin (2020-2025)
11.1.5 AbbVie Ocular Gene Therapy Revenue by Product in 2024
11.1.6 AbbVie Ocular Gene Therapy Revenue by Application in 2024
11.1.7 AbbVie Ocular Gene Therapy Revenue by Geographic Area in 2024
11.1.8 AbbVie Ocular Gene Therapy SWOT Analysis
11.1.9 AbbVie Recent Developments
11.2 MeriaGTx
11.2.1 MeriaGTx Corporation Information
11.2.2 MeriaGTx Business Overview
11.2.3 MeriaGTx Ocular Gene Therapy Product Features and Attributes
11.2.4 MeriaGTx Ocular Gene Therapy Revenue and Gross Margin (2020-2025)
11.2.5 MeriaGTx Ocular Gene Therapy Revenue by Product in 2024
11.2.6 MeriaGTx Ocular Gene Therapy Revenue by Application in 2024
11.2.7 MeriaGTx Ocular Gene Therapy Revenue by Geographic Area in 2024
11.2.8 MeriaGTx Ocular Gene Therapy SWOT Analysis
11.2.9 MeriaGTx Recent Developments
11.3 Regenxbio
11.3.1 Regenxbio Corporation Information
11.3.2 Regenxbio Business Overview
11.3.3 Regenxbio Ocular Gene Therapy Product Features and Attributes
11.3.4 Regenxbio Ocular Gene Therapy Revenue and Gross Margin (2020-2025)
11.3.5 Regenxbio Ocular Gene Therapy Revenue by Product in 2024
11.3.6 Regenxbio Ocular Gene Therapy Revenue by Application in 2024
11.3.7 Regenxbio Ocular Gene Therapy Revenue by Geographic Area in 2024
11.3.8 Regenxbio Ocular Gene Therapy SWOT Analysis
11.3.9 Regenxbio Recent Developments
11.4 GenSight Biologics
11.4.1 GenSight Biologics Corporation Information
11.4.2 GenSight Biologics Business Overview
11.4.3 GenSight Biologics Ocular Gene Therapy Product Features and Attributes
11.4.4 GenSight Biologics Ocular Gene Therapy Revenue and Gross Margin (2020-2025)
11.4.5 GenSight Biologics Ocular Gene Therapy Revenue by Product in 2024
11.4.6 GenSight Biologics Ocular Gene Therapy Revenue by Application in 2024
11.4.7 GenSight Biologics Ocular Gene Therapy Revenue by Geographic Area in 2024
11.4.8 GenSight Biologics Ocular Gene Therapy SWOT Analysis
11.4.9 GenSight Biologics Recent Developments
11.5 Astellas
11.5.1 Astellas Corporation Information
11.5.2 Astellas Business Overview
11.5.3 Astellas Ocular Gene Therapy Product Features and Attributes
11.5.4 Astellas Ocular Gene Therapy Revenue and Gross Margin (2020-2025)
11.5.5 Astellas Ocular Gene Therapy Revenue by Product in 2024
11.5.6 Astellas Ocular Gene Therapy Revenue by Application in 2024
11.5.7 Astellas Ocular Gene Therapy Revenue by Geographic Area in 2024
11.5.8 Astellas Ocular Gene Therapy SWOT Analysis
11.5.9 Astellas Recent Developments
11.6 Neurophth Therapeutics
11.6.1 Neurophth Therapeutics Corporation Information
11.6.2 Neurophth Therapeutics Business Overview
11.6.3 Neurophth Therapeutics Ocular Gene Therapy Product Features and Attributes
11.6.4 Neurophth Therapeutics Ocular Gene Therapy Revenue and Gross Margin (2020-2025)
11.6.5 Neurophth Therapeutics Recent Developments
11.7 Innostellar Biotherapeutics
11.7.1 Innostellar Biotherapeutics Corporation Information
11.7.2 Innostellar Biotherapeutics Business Overview
11.7.3 Innostellar Biotherapeutics Ocular Gene Therapy Product Features and Attributes
11.7.4 Innostellar Biotherapeutics Ocular Gene Therapy Revenue and Gross Margin (2020-2025)
11.7.5 Innostellar Biotherapeutics Recent Developments
11.8 Exegenesis Bio
11.8.1 Exegenesis Bio Corporation Information
11.8.2 Exegenesis Bio Business Overview
11.8.3 Exegenesis Bio Ocular Gene Therapy Product Features and Attributes
11.8.4 Exegenesis Bio Ocular Gene Therapy Revenue and Gross Margin (2020-2025)
11.8.5 Exegenesis Bio Recent Developments
11.9 Zhongyin Technology
11.9.1 Zhongyin Technology Corporation Information
11.9.2 Zhongyin Technology Business Overview
11.9.3 Zhongyin Technology Ocular Gene Therapy Product Features and Attributes
11.9.4 Zhongyin Technology Ocular Gene Therapy Revenue and Gross Margin (2020-2025)
11.9.5 Zhongyin Technology Recent Developments
12 Ocular Gene TherapyIndustry Chain Analysis
12.1 Ocular Gene Therapy Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Ocular Gene Therapy Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Ocular Gene Therapy Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
AbbVie
REGENXBIO
GenSight Biologics
Astellas
MeriaGTx
Neurophth Therapeutics
Innostellar Biotherapeutics
Exegenesis Bio
Zhongyin Technology
List of Tables
 Table 1. Global Ocular Gene Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Ocular Gene Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Ocular Gene Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Ocular Gene Therapy Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Ocular Gene Therapy Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Ocular Gene Therapy Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Ocular Gene Therapy Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Ocular Gene Therapy by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ocular Gene Therapy as of 2024)
 Table 11. Global Ocular Gene Therapy Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Ocular Gene Therapy Companies Headquarters
 Table 13. Global Ocular Gene Therapy Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Ocular Gene Therapy Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Ocular Gene Therapy Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Ocular Gene Therapy Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Ocular Gene Therapy Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Ocular Gene Therapy High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Ocular Gene Therapy Growth Accelerators and Market Barriers
 Table 25. North America Ocular Gene Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Ocular Gene Therapy Growth Accelerators and Market Barriers
 Table 27. Europe Ocular Gene Therapy Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Ocular Gene Therapy Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Ocular Gene Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Ocular Gene Therapy Investment Opportunities and Key Challenges
 Table 31. Central and South America Ocular Gene Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Ocular Gene Therapy Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Ocular Gene Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. AbbVie Corporation Information
 Table 35. AbbVie Description and Major Businesses
 Table 36. AbbVie Product Features and Attributes
 Table 37. AbbVie Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. AbbVie Revenue Proportion by Product in 2024
 Table 39. AbbVie Revenue Proportion by Application in 2024
 Table 40. AbbVie Revenue Proportion by Geographic Area in 2024
 Table 41. AbbVie Ocular Gene Therapy SWOT Analysis
 Table 42. AbbVie Recent Developments
 Table 43. MeriaGTx Corporation Information
 Table 44. MeriaGTx Description and Major Businesses
 Table 45. MeriaGTx Product Features and Attributes
 Table 46. MeriaGTx Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. MeriaGTx Revenue Proportion by Product in 2024
 Table 48. MeriaGTx Revenue Proportion by Application in 2024
 Table 49. MeriaGTx Revenue Proportion by Geographic Area in 2024
 Table 50. MeriaGTx Ocular Gene Therapy SWOT Analysis
 Table 51. MeriaGTx Recent Developments
 Table 52. Regenxbio Corporation Information
 Table 53. Regenxbio Description and Major Businesses
 Table 54. Regenxbio Product Features and Attributes
 Table 55. Regenxbio Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Regenxbio Revenue Proportion by Product in 2024
 Table 57. Regenxbio Revenue Proportion by Application in 2024
 Table 58. Regenxbio Revenue Proportion by Geographic Area in 2024
 Table 59. Regenxbio Ocular Gene Therapy SWOT Analysis
 Table 60. Regenxbio Recent Developments
 Table 61. GenSight Biologics Corporation Information
 Table 62. GenSight Biologics Description and Major Businesses
 Table 63. GenSight Biologics Product Features and Attributes
 Table 64. GenSight Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. GenSight Biologics Revenue Proportion by Product in 2024
 Table 66. GenSight Biologics Revenue Proportion by Application in 2024
 Table 67. GenSight Biologics Revenue Proportion by Geographic Area in 2024
 Table 68. GenSight Biologics Ocular Gene Therapy SWOT Analysis
 Table 69. GenSight Biologics Recent Developments
 Table 70. Astellas Corporation Information
 Table 71. Astellas Description and Major Businesses
 Table 72. Astellas Product Features and Attributes
 Table 73. Astellas Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Astellas Revenue Proportion by Product in 2024
 Table 75. Astellas Revenue Proportion by Application in 2024
 Table 76. Astellas Revenue Proportion by Geographic Area in 2024
 Table 77. Astellas Ocular Gene Therapy SWOT Analysis
 Table 78. Astellas Recent Developments
 Table 79. Neurophth Therapeutics Corporation Information
 Table 80. Neurophth Therapeutics Description and Major Businesses
 Table 81. Neurophth Therapeutics Product Features and Attributes
 Table 82. Neurophth Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. Neurophth Therapeutics Recent Developments
 Table 84. Innostellar Biotherapeutics Corporation Information
 Table 85. Innostellar Biotherapeutics Description and Major Businesses
 Table 86. Innostellar Biotherapeutics Product Features and Attributes
 Table 87. Innostellar Biotherapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Innostellar Biotherapeutics Recent Developments
 Table 89. Exegenesis Bio Corporation Information
 Table 90. Exegenesis Bio Description and Major Businesses
 Table 91. Exegenesis Bio Product Features and Attributes
 Table 92. Exegenesis Bio Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. Exegenesis Bio Recent Developments
 Table 94. Zhongyin Technology Corporation Information
 Table 95. Zhongyin Technology Description and Major Businesses
 Table 96. Zhongyin Technology Product Features and Attributes
 Table 97. Zhongyin Technology Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 98. Zhongyin Technology Recent Developments
 Table 99. Raw Materials Key Suppliers
 Table 100. Distributors List
 Table 101. Market Trends and Market Evolution
 Table 102. Market Drivers and Opportunities
 Table 103. Market Challenges, Risks, and Restraints
 Table 104. Research Programs/Design for This Report
 Table 105. Key Data Information from Secondary Sources
 Table 106. Key Data Information from Primary Sources


List of Figures
 Figure 1. Ocular Gene Therapy Product Picture
 Figure 2. Global Ocular Gene Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Gene Replacement Technology Product Picture
 Figure 4. Gene Editing Technology Product Picture
 Figure 5. Others Product Picture
 Figure 6. Global Ocular Gene Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 7. Hospitals
 Figure 8. Diagnostics Centers
 Figure 9. Research Institutes
 Figure 10. Ocular Gene Therapy Report Years Considered
 Figure 11. Global Ocular Gene Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Ocular Gene Therapy Revenue (2020-2031) & (US$ Million)
 Figure 13. Global Ocular Gene Therapy Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 14. Global Ocular Gene Therapy Revenue Market Share by Region (2020-2031)
 Figure 15. Global Ocular Gene Therapy Revenue Market Share Ranking (2024)
 Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 17. Gene Replacement Technology Revenue Market Share by Player in 2024
 Figure 18. Gene Editing Technology Revenue Market Share by Player in 2024
 Figure 19. Others Revenue Market Share by Player in 2024
 Figure 20. Global Ocular Gene Therapy Revenue Market Share by Type (2020-2031)
 Figure 21. Global Ocular Gene Therapy Revenue Market Share by Application (2020-2031)
 Figure 22. North America Ocular Gene Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 23. North America Top 5 Players Ocular Gene Therapy Revenue (US$ Million) in 2024
 Figure 24. North America Ocular Gene Therapy Revenue (US$ Million) by Type (2020 - 2031)
 Figure 25. North America Ocular Gene Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 26. US Ocular Gene Therapy Revenue (2020-2031) & (US$ Million)
 Figure 27. Canada Ocular Gene Therapy Revenue (2020-2031) & (US$ Million)
 Figure 28. Mexico Ocular Gene Therapy Revenue (2020-2031) & (US$ Million)
 Figure 29. Europe Ocular Gene Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 30. Europe Top 5 Players Ocular Gene Therapy Revenue (US$ Million) in 2024
 Figure 31. Europe Ocular Gene Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 32. Europe Ocular Gene Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 33. Germany Ocular Gene Therapy Revenue (2020-2031) & (US$ Million)
 Figure 34. France Ocular Gene Therapy Revenue (2020-2031) & (US$ Million)
 Figure 35. U.K. Ocular Gene Therapy Revenue (2020-2031) & (US$ Million)
 Figure 36. Italy Ocular Gene Therapy Revenue (2020-2031) & (US$ Million)
 Figure 37. Russia Ocular Gene Therapy Revenue (2020-2031) & (US$ Million)
 Figure 38. Asia-Pacific Ocular Gene Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 39. Asia-Pacific Top 8 Players Ocular Gene Therapy Revenue (US$ Million) in 2024
 Figure 40. Asia-Pacific Ocular Gene Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 41. Asia-Pacific Ocular Gene Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 42. Indonesia Ocular Gene Therapy Revenue (2020-2031) & (US$ Million)
 Figure 43. Japan Ocular Gene Therapy Revenue (2020-2031) & (US$ Million)
 Figure 44. South Korea Ocular Gene Therapy Revenue (2020-2031) & (US$ Million)
 Figure 45. Australia Ocular Gene Therapy Revenue (2020-2031) & (US$ Million)
 Figure 46. India Ocular Gene Therapy Revenue (2020-2031) & (US$ Million)
 Figure 47. Indonesia Ocular Gene Therapy Revenue (2020-2031) & (US$ Million)
 Figure 48. Vietnam Ocular Gene Therapy Revenue (2020-2031) & (US$ Million)
 Figure 49. Malaysia Ocular Gene Therapy Revenue (2020-2031) & (US$ Million)
 Figure 50. Philippines Ocular Gene Therapy Revenue (2020-2031) & (US$ Million)
 Figure 51. Singapore Ocular Gene Therapy Revenue (2020-2031) & (US$ Million)
 Figure 52. Central and South America Ocular Gene Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 53. Central and South America Top 5 Players Ocular Gene Therapy Revenue (US$ Million) in 2024
 Figure 54. Central and South America Ocular Gene Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 55. Central and South America Ocular Gene Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 56. Brazil Ocular Gene Therapy Revenue (2020-2025) & (US$ Million)
 Figure 57. Argentina Ocular Gene Therapy Revenue (2020-2025) & (US$ Million)
 Figure 58. Middle East and Africa Ocular Gene Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 59. Middle East and Africa Top 5 Players Ocular Gene Therapy Revenue (US$ Million) in 2024
 Figure 60. South America Ocular Gene Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 61. Middle East and Africa Ocular Gene Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 62. GCC Countries Ocular Gene Therapy Revenue (2020-2025) & (US$ Million)
 Figure 63. Israel Ocular Gene Therapy Revenue (2020-2025) & (US$ Million)
 Figure 64. Egypt Ocular Gene Therapy Revenue (2020-2025) & (US$ Million)
 Figure 65. South Africa Ocular Gene Therapy Revenue (2020-2025) & (US$ Million)
 Figure 66. Ocular Gene Therapy Industry Chain Mapping
 Figure 67. Channels of Distribution (Direct Vs Distribution)
 Figure 68. Bottom-up and Top-down Approaches for This Report
 Figure 69. Data Triangulation
 Figure 70. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Global Optogenetic Retinal Gene Therapy Market Research Report 2024
Global Optogenetic Gene Therapy Market Research Report 2024
Global Non viral Vectors Gene Therapy Market Research Report 2025
Global In Vitro Gene Therapy Market Research Report 2025
Global Gene Therapy in Oncology Market Research Report 2024
Global Cell and Gene Therapy Solutions Market Research Report 2025
Global Gene Editing Therapy Market Research Report 2024
Global Viral Vector Based Gene Therapy Market Research Report 2025
Global Gene Therapy Drug Delivery Tube Market Research Report 2024
Global Ophthalmic AAV Gene Therapy Market Research Report 2024
Adeno Associated Virus AAV Gene Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Gene Therapy Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hemophilia Gene Therapy Market Research Report 2025
Gene Therapy Products Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Gene Cell Therapy CDMO Market Research Report 2024
Gene Therapy Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Viral Vectors Non Viral Vectors and Gene Therapy Manufacturing Market Research Report 2024
Global Nucleic Acid Based Gene Therapeutics Market Research Report 2024
Gene Therapy For Heart Failure Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cell and Gene Therapy CDMO Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions